SCHEMBL13068898

SCHEMBL13068898

COCCCOc1cc(C)ccc1OC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.61
L3MBTL1 Q9Y468 14/20 0.59
MAPT P10636 11/20 0.59
HPGD P15428 7/20 0.59
NPC1 O15118 4/20 0.59
RAB9A P51151 4/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
TDP1 Q9NUW8 4/20 0.59
CYP2C9 P11712 3/20 0.58
CYP2C19 P33261 3/20 0.58
CYP1A2 P05177 2/20 0.58
CYP3A4 P08684 1/20 0.58
L3MBTL4 Q8NA19 1/20 0.57
L3MBTL3 Q96JM7 1/20 0.57
ALDH1A1 P00352 3/20 0.56
MAPK1 P28482 2/20 0.56
NPSR1 Q6W5P4 2/20 0.56
POLB P06746 2/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3373256 0.93 L3MBTL1 (0.67) ACHEL3MBTL1MAPTHPGDNPC1
SCHEMBL12781858 0.91 ACHE (0.63) ACHEL3MBTL1MAPTHPGDNPC1
SCHEMBL13433992 0.86 L3MBTL1 (0.53) L3MBTL1MAPTHPGDNPC1RAB9A
SCHEMBL3069940 0.86 L3MBTL1 (0.65) L3MBTL1MAPTHPGDNPC1RAB9A
SCHEMBL11963361 0.85 ACHE (0.61) ACHEL3MBTL1MAPTHPGDNPC1
SCHEMBL13433961 0.84 L3MBTL1 (0.50) L3MBTL1MAPTHPGDNPC1RAB9A
SCHEMBL13433956 0.84 ACHE (0.59) ACHEL3MBTL1MAPTHPGDNPC1
SCHEMBL13631020 0.84 ACHE (0.59) ACHEL3MBTL1MAPTHPGDNPC1
SCHEMBL3814694 0.84 ACHE (0.59) ACHEL3MBTL1MAPTHPGDNPC1
SCHEMBL11963234 0.83 ACHE (0.63) ACHEL3MBTL1MAPTHPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019177937-A1 SUBSTITUTED 2-PYRIDONE TRICYCLIC COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2019-09-19 WO disclosed
EP-1948643-B1 3-ALKYL-5- (4-ALKYL-5-OXO-TETRAHYDROFURAN-2-YL) PYRROLIDIN-2-ONE DERIVATIVES AS INTERMEDIATES IN THE SYNTHESIS OF RENIN INHIBITORS NOVARTIS AG (CH) 2013-06-05 EP disclosed
EP-1863477-B1 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION NOVARTIS AG (CH) 2010-11-03 EP disclosed
US-20100056497-A1 AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2010-03-04 US disclosed
US-20100056497-A1 AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD (JP) 2010-03-04 US disclosed
EP-2119702-A1 AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-11-18 EP disclosed
US-20090270417-A1 Organic Compounds NOVARTIS AG (CH) 2009-10-29 US disclosed
WO-2007045420-A2 3-ALKYL-5- (4-ALKYL-5-OXO-TETRAHYDROFUTRAN-2-YL) PYRROLIDIN-2-ONE DERIVATIVES AS INTERMEDIATES IN THE SYNTHESIS OF RENIN INHIBITORS NOVARTIS AG (CH) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270417-A1 Organic Compounds REN, ACE, OTC ACHE 835/4885L3MBTL1 4246/4885MAPT 932/4885
US-20100056497-A1 AMIDE DERIVATIVE REN, AGTR1, AGTR2 ACHE 770/4885L3MBTL1 3531/4885MAPT 3478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.